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Abstract: Benzimidazole-based nucleotides and dinucleotides
have been synthesised to increase the range of chemical tools avail-
able to probe the NAD+ biology space. They were examined for
their reactivity in alkylation-type reactions, where they yielded un-
stable alkylated heteoaromatic adducts, both chemically and enzy-
matically. While unsuited for NAD+ cyclases, these NAD+
analogues could be viable substrates for non-adenine modifying
NAD+-dependent enzyme classes.
Key words: nucleotides, benzimidazoribosyl nucleosides, phos-
phorylation, cyclic adenosine diphosphoribose, enzymes
There is a need for efficacious methods to access novel
analogues of nicotinamide adenine dinucleotide (NAD+)
following the recent discoveries of its role in age-related
diseases, and therefore probe the vast range of biological
events it regulates. For instance, cADPR 1 is an intracel-
lular NAD+ metabolite, generated by intramolecular cy-
clisation of NAD+ catalysed by an adenosine diphosphate
ribosyl transferase (ART).1 cADPR has now been firmly
established as a second messenger, capable of initiating
Ca2+ release from intracellular stores mediated by the
Ryanodine receptor.2 CD38, the human ART cyclase
which also possesses hydrolase activity, is a membrane-
bound glycoprotein which has been linked to a range of
cellular event regulations including cell activation and
muscle contraction to name only a few.3,4 Importantly,
CD38’s expression has been linked to poor prognosis in
chronic lymphocytic leukaemia.5
This cyclase is able to convert a wide range of substrates
into cyclic analogues (e.g. nicotinamide N6-ethenoade-
nine dinucleotide,6 a known fluorescent cADPR ana-
logue), which have been used to probe the physiological
properties of cADPR and the catalytic properties of this
enzyme.7 Since the discovery of cADPR, both cADPR
and NAD+ derivatives such as 3′-F-NAD+8 have been ex-
tensively used in crystal studies of a number of NAD+-
converting enzymes,9 including that responsible for the
cyclisation of NAD+ to cADPR. In addition, much of to-
day’s knowledge about cADPR-induced Ca2+-signalling
pathway was gained due to the wide range of the cADPR
analogues synthesised (2–18).10–25
The synthesis of cADPR analogues (2–18; Figure 1) from
novel nucleoside precursors has been achieved using ei-
ther a total chemical route or a chemoenzymatic ap-
proach.10–25 The chemical route is mostly used to access
Figure 1  cADPR and analogues successfully synthesised and evaluated for cyclase activity
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cADPR analogues unattainable through enzymatic cycli-
sation reactions.22,26 The chemoenzymatic approach to
cADPR derivatives is based on the chemical synthesis of
NAD+ analogues followed by an enzymatic cyclisation us-
ing the commercially available adenosine diphosphoribo-
syl cyclase isolated from Aplysia californica (ADPRC).
This approach is facilitated by the fact that this latter en-
zyme has high cyclase activity and low substrate specific-
ity.27
While many of these compounds have been designed to
investigate the SAR of cADPR for its receptor and its role
on calcium release, compounds which inform on the cy-
clase activity during the cell cycle have been lacking.
Therefore, we have been particularly interested in access-
ing base-modified analogues of NAD+ that can be alkylat-
ed through cyclisation by this class of enzyme and
generate analogues which exhibit a change in fluores-
cence. Till now, neither benzimidazole nor azabenzimid-
azole NAD+ and cADPR derivatives have been employed
to probe the cyclase activity and calcium release pathway,
respectively.28
Building on our recently reported three-step one-pot
method to synthesise aryl- and heteroaryl-substituted ben-
zimidazoribosyl nucleosides,29 four of the most readily
available nucleoside analogues were selected as precur-
sors in an attempt to generate novel benzimidazole-based
cADPR analogues.
It was anticipated that the dinucleotides generated from 19
and 20 would cyclise through the imidazole ring via an
N7–N9 cyclisation to generate analogues of 2 and 3 while
the nucleoside 21 could cyclise via the pyridyl nitrogen
and the nucleoside 22 via the fused pyridyl nitrogen.
These four nucleosides provide means to access three
types of cyclised nucleotides (Scheme 1).
Scheme 1  Nucleotide intermediates 19–22
With these nucleoside analogues at hand,29 the parameters
required for the synthesis of the 5′- phosphate monoesters
were to be optimised. Woenckhaus reported the success-
ful preparation of benzimidazole ribonucleotides 19 and
22 while employing a dicyclohexylcarbodiimide coupling
reaction in pyridine.30 This approach required the barium
salt form of an appropriately protected phosphate mon-
oester, the 2′,3′-diisopropylidene-protected nucleosides
and an extensive deprotection sequence. We therefore
aimed to implement a more straightforward phosphoryla-
tion protocol using the fully deprotected nucleosides.
Consequently, the selective 5′- nucleoside monophos-
phate was obtained using the Yoshikawa methodology by
reaction with POCl3 in PO(OEt)3 with the desired free
phosphate achieved through subsequent hydrolysis.31 For
this set of benzimidazole nucleoside derivatives, optimis-
ation of the Yoshikawa reaction method was first conduct-
ed on nucleoside 19 and included one molar equivalent of
nucleoside dissolved in a minimal volume of triethylphos-
phate (TEP) by heating,32 then cooled to 0 °C, followed by
the addition of three molar equivalents of phosphorus
oxychloride. The reactions were quenched by the addition
of ice (Scheme 2).
Scheme 2  Phosphorylation of 1-(β-D-ribofuranosyl)benzimidazole
and azabenzimidazoles 19–22 using phosphorus oxychloride
After overcoming the challenges of TEP removal using
chloroform, purification of the nucleotides proved equally
difficult. The HPLC purification using ion-exchange
chromatography [Q-sepharose Fast Flow or diethylami-
noethanol (DEAE) sepharose] proved unsuited as the re-
moval of excess buffered salts could not be accomplished
satisfyingly. Nor was the use of C-8-Reversed-Phase (RP)
chromatography. HPLC purification of compound 1933
was finally achieved in 70% yield using C-18-RP column
chromatography with a linear elution gradient of ammoni-
um formate against methanol.
The phosphorylation reaction and the optimised purifica-
tion procedure were subsequently applied to isolate the
pure nucleotides 2034 and 21,35 in 62% and 25% yield, re-
spectively. Unfortunately, unlike in the sequence reported
by Woenckhaus, the nucleoside precursor to nucleotide 22
failed to undergo the Yoshikawa phosphorylation reaction
and crude NMR analysis indicated the appearance of
quantitative isolation of azabenzimidazole heterocycle 23
(Scheme 3).
Despite the nucleoside precursor to 23 having been syn-
thesised nearly 50 years ago,30,36 its chemical instability
under acidic conditions has not been reported. The Yoshi-
kawa reaction outcome indicates that the azaaryl nitrogen
is the most basic and nucleophilic nitrogen of the het-
eroaromatic moiety, and likely to yield an NAD+ analogue
unsuitable for enzymatic conversion to the corresponding
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cADPR analogue, as it is likely to be a chemically unsta-
ble species. As a consequence, this class of nucleotide was
not pursued.
Phosphoroimidazolides have been widely used to access
pyrophosphate bonds.37 These species can be easily pre-
pared via the reaction between a nucleotide and 1,1′-car-
bonyldiimidazole (CDI) in the presence of a base. The
subsequent Mn2+- or Cd2+-catalysed pyrophosphate bond
formation led to a range of NAD+ analogues and nucleo-
tide triphosphates, in neutral aqueous conditions.15,38,39
Nicotinamide mononucleotide (NMN), a notoriously un-
stable molecule towards nucleophiles, was activated to the
imidazolidate 24 with CDI in DMF, and the crude was
used for its subsequent reaction with 19–21, where the py-
rophosphate bond formation could be detected by 31P
NMR. Yet, even after extended reaction time, conversion
yields to the pyrophosphate remained low. This lack of re-
activity is likely related to the low solubility of NMN in
DMF, and purification of the crude mixture using a DEAE
sepharose anion-exchange column at pH 5 led to the iso-
lation of 25 only in less than 10% yield. Woenckhaus re-
ported similarly low yields, even after extended reaction
time for the preparation in pyridine of this dinucleotide
under dicyclohexylcarbodiimide conditions.30
Consequently, the reaction was repeated changing the or-
der of the reactants and conducted as a two-step one-pot
process (Scheme 4). Following the generation of the phos-
phoroimidazolate derivative of nucleotide 19 using the
CDI methodology, addition of β-NMN in a premixed
solution of DMF and formamide, yielded the pyrophos-
phate derivative 25 as detected by 31P NMR (D2O, br, 2 ×
P; δ = –10.95, –12.08 ppm).40 After optimisation of the
purification methods, HPLC purification on a DEAE sep-
harose column with an ammonium formate buffer at pH 5,
the dinucleotide 2541 was isolated in 32% yield (as mea-
sured by UV and Ames assays42). The pyrophosphate cou-
pling of the phenyl-substituted benzimidazole nucleotide
20 with β-NMN was performed in the same manner and
the NAD+ analogue 2643 was isolated in 43% yield
(Scheme 4).
Finally, the coupling reaction between the phosphoroim-
idazolide derivative of pyridyl-substituted nucleotide 22
(Scheme 2) and NMN proved unsuccessful regardless of
the sequence applied. The unsuccessful outcome might be
due to the formation of an internal pyridinium phosphate
salt which decreases the nucleophilicity of the nucleoside
phosphate and decrease its reactivity towards CDI. This
statement is supported by the fact that the phosphoimidaz-
olate, intermediate to compound 27, could not be detected
by 31P NMR in the first step of the reaction.
Finally, when attempts were made at establishing the use-
fulness of these dinucleotides as substrates for the Aplysia
ART cyclase,44 no cyclic product could be detected by
HPLC–UV (2–24 h incubation time, r.t.; detection at λ =
254 nm; SAX column) even though the NAD+ deriva-
tives’ content declined over time. For the benzimidazolide
25, the ADPR product generated by hydrolysis of the pu-
tative cyclised product would be the same as that generat-
ed by simple glycosidic cleavage of the nicotinamide
riboside bond. So to investigate whether the decrease in
NAD+ analogues’ content over time was due to a lack of
reactivity towards the cyclase combined to a lack of sta-
bility of the glycosidic nicotinamide bond, or due to the
formation of a cyclic ADPR analogue followed by hydro-
lysis, the nucleoside precursors to 19–22 were alkylated in
THF–H2O solution with MeI. The nucleosides rapidly de-
composed to the respective methylated nucleobase and
ribose derivatives, indicating an unstable nucleosidic
C1–‘N7’ bond being generated upon alkylation.
Scheme 3  Decomposition of azabenzimidazole under Yoshikawa
conditions
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While this chemical behaviour renders these modified
NAD+ compounds inappropriate as cADPR analogue pre-
cursors, compound 26 is potentially well suited to differ-
entiate between cyclase and hydrolase activity, since for
the former, cyclisation followed by hydrolysis generates
ADPR and the isomerised ADPR (‘N9’ vs ‘N7’ linkage),
while for the latter, only ADPR is generated. Unfortunate-
ly under the conditions developed in this work, the break-
down product could only be confirmed by MS as ADPR-
like compounds are difficult to detect by HPLC–UV fol-
lowing SAX separation as they are poorly eluted, thus pre-
venting differentiation between the two mechanisms. Yet,
this property is potentially useful to examine changes in
cyclase vs. hydrolase activity associated with mutations or
post-translational modifications, as well as substrate spec-
ificity. Work in this area is undergoing to determine the
product distribution profiles by methods other than chro-
matographic separation. However, in view of the chemi-
cal space offered by the benzimidazole ring for chemical
modifications, a potential application for this class of
functionalisable dinucleotides is their use as sirtuins and
selective substrates for ADP-ribosyltransferases, where
amino group substitution on the benzimidazole would en-
hance opportunities for sirtuin-specific binding and there-
fore probing (e.g. as demonstrated for NAD+ analogues
where selective SirT2 vs SirT1 recognition was
achieved).45 This is in addition to the substrate specificity
that some of the benzimidazolide dinucleotides have al-
ready demonstrated for a range of NAD+-dependent de-
hydrogenases.30
In conclusion, out of the four benzimidazole riboside de-
rivatives, putative building blocks of cADPR analogues,
two benzimidazole NAD+ analogues have been synthe-
sised effectively, yet in moderate yields. Due to the re-
duced stability of the protonated or alkylated
benzimidazolide nucleotides, none of these building
blocks yielded cADPR analogues, however they prove to
be potentially useful as reporting probes for cyclase ver-
sus hydrolase activity. Additionally, they could potential-
ly be used to probe other NAD+-dependent processes
which include ADP ribosylation of proteins and sirtuin-
catalysed deacetylations, an enzymatic event where the
nucleobase is not chemically modified.46
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1-N-(5′-Phosphato-β-D-ribofuranosyl)benzimidazole 
(19): A 70% yield of compound 19 was achieved when 
purification was performed on reverse-phase column 
(Varian: prepacked C18 column), product elution was 
carried out using a linear gradient 5–90% of 10 mM AF 
(adjusted to pH 5) against MeOH. 1H NMR (600 MHz, 
D2O): δ = 9.40 (s, 1 H), 7.87–7.93 (m, 1 H), 7.78–7.86 (m, 1 
H), 7.58–7.66 (m, 2 H), 6.27 (d, J = 4.2 Hz, 1 H), 4.60 (t, J 
= 4.2 Hz, 1 H), 4.39–4.47 (m, 2 H), 4.20–4.27 (m, 1 H), 
4.08–4.16 (m, 1 H). 13C NMR (150 MHz, D2O): δ = 138.3, 
131.3, 129.7, 127.2, 126.9, 115.0, 113.2, 90.9, 84.5 (d, J = 
8.8 Hz), 75.1, 69.7, 63.7 (d, J = 4.7 Hz). 31P NMR (162 MHz, 
D2O): δ = 0.21. HPLC: tR = 12.32 min. MS (ES): m/z [M + 
H]+ calcd for C12H15N2O7P: 331.0695; found: 331.0703.
(34) 5-Phenyl-1-N-(5′-Phosphato-β-D-ribofuranosyl)-
benzimidazole (20): A 62% isolated yield of compound 20 
was achieved when purification was performed on reverse-
phase column (Varian: prepacked C18 column), product 
elution was carried out using a linear gradient 5–90% of 10 
mM AF (adjusted to pH 5) against MeOH. 1H NMR (300 
MHz, D2O): δ = 8.54–8.66 (m, 1 H), 7.97 (m, 1 H), 7.79–
7.87 (m, 1 H), 7.53–7.75 (m, 3 H), 7.41 (t, J = 7.3 Hz, 2 H), 
7.31 (t, J = 7.3 Hz, 1 H), 6.08 (d, J = 6.2 Hz, 1 H), 4.55–4.62 
(m, 1 H), 4.36–4.48 (m, 1 H), 4.22–4.33 (m, 1 H), 4.06–4.16 
(m, 2 H). 31P NMR (121 MHz, D2O): δ = 0.49. HPLC: tR = 
12.88 min. MS (ES): m/z [M – H]– calcd for C18H18N2O7P: 
405.0852; found: 405.0869.
(35) 2-(3′-Pyridyl)-1-N-(5′′-Phosphato-β-D-ribofuranosyl)-
benzimidazole (21): A 25% yield of compound 21 was 
achieved when the initial purification was performed on ion-
exchange resin (DEAE Sepharose Fast Flow) using gradient 
miliQ water against 0.1 M triethylamine formate (TEAF) at 
pH 5 with 10% of MeOH (0–100%) followed by reverse-
phase purification (Varian: prepacked C18 column), product 
elution was carried out using a linear gradient 5–90% of 10 
mM AF (adjusted to pH 5) against MeOH. 1H NMR (300 
MHz, D2O): δ = 8.74 (s, 1 H), 8.64 (d, J = 4.2 Hz, 1 H), 8.08–
8.17 (m, 1 H), 7.96 (d, J = 7.6 Hz, 1 H), 7.70 (d, J = 7.3 Hz, 
1 H), 7.58 (dd, J = 5.1, 7.9 Hz, 1 H), 7.30–7.43 (m, 2 H), 5.80 
(d, J = 7.7 Hz, 1 H), 4.82 (dd, J = 6.3, 7.6 Hz, 1 H), 4.35 (dd, 
J = 3.1, 6.3 Hz, 1 H), 4.10–4.16 (m, 1 H), 3.99–4.03 (m, 2 
H). 13C NMR (100 MHz, D2O): δ = 150.5, 149.0, 142.0, 
138.7, 132.6, 125.6, 124.6, 124.4, 124.1, 119.1, 113.9, 89.0, 
84.2 (d, J = 8.7 Hz), 70.7, 69.6, 64.1 (d, J = 4.8 Hz). 31P 
NMR (121 MHz, D2O): δ = 2.24. HPLC: tR = 15.38 min. MS 
(ES): m/z [M + H]+ calcd for C17H19N3O7P: 408.0961; found: 
408.0952.
(36) Mizuno, Y.; Itoh, T.; Saito, K. J. Org. Chem. 1964, 29, 2611.
(37) Cramer, F.; Schaller, H.; Staab, H. A. Chem. Ber. 1961, 94, 
1612.
(38) Zhang, B.; Bailey, V. C.; Potter, B. V. L. J. Org. Chem. 
2008, 73, 1693.
(39) (a) Ko, H.; Fricks, I.; Ivanov, A. A.; Harden, T. K.; 
Jacobson, K. A. J. Med. Chem. 2007, 50, 2030. (b) Crauste, 
C.; Périgaud, C.; Peyrottes, S. J. Org. Chem. 2009, 74, 9165.
(40) General Procedure for the CDI-Mediated Pyrophosphate 
Bond Formation: Prior to the reaction a stock solution of 
NMN was prepared by dissolving NMN (100 mg) in anhyd 
DMF (1 ml) and anhyd formamide (1 mL). CDI (2.5 equiv) 
and Et3N (2 equiv) were then added to a solution of 
nucleotide (1.2 equiv) in anhyd DMF (0.5 mL). The reaction 
was stirred for 12 h at r.t. The reaction was then quenched 
with anhyd MeOH and evaporated to dryness. The resulting 
solid was dissolved in new portion of anhyd DMF (0.5 mL) 
and a solution of NMN (1 equiv) was added. The reaction 
was followed by 31P NMR and once the imidazolate peak 
had disappeared, the reaction was diluted with MilliQ water 
and applied on DEAE sepharose. Isolation of the NAD 
analogues was performed using ion-exchange resin (DEAE 
Sepharose Fast Flow) using gradient MilliQ water against 
0.1 M ammonium formate buffer (AF) at pH 5 with 10% of 
MeOH (0–100%).
(41) Nicotinamide Benzimidazole Dinucleotide (25): The 
product was isolated after 48 h in 32% of yield. 1H NMR 
(400 MHz, D2O): δ = 9.12 (s, 1 H), 8.98 (d, J = 6.2 Hz, 1 H), 
8.61 (d, J = 8.1 Hz, 1 H), 8.38 (s, 1 H), 7.94–8.07 (m, 1 H), 
7.58 (d, J = 7.58, 15.6 Hz, 2 H), 7.25–7.34 (m, 3 H), 6.98 (d, 
J = 7.8 Hz, 1 H), 5.91 (dd, J = 5.9, 9.3 Hz, 2 H), 3.98–4.51 
(m, 10 H). 13C NMR (100 MHz, D2O): δ = 180.0, 171.0, 
145.4, 142.1, 142.1, 139.7, 133.4, 129.9, 128.5, 124.2, 
123.5, 121.6, 119.1, 114.9, 111.5, 99.9, 88.2 (d), 83.7 (d), 
77.5, 72.9, 70.4, 70.10, 65.59 (d), 64.81 (d). 31P NMR (162 
MHz, D2O): δ = –10.95 to –12.08 (m, P–O–P). MS (ES): m/z 
[M – H]– calcd for C23H28N4O14P2: 646.1077; found: 
646.1078. HPLC: tR = 7.17 min.
(42) Ames, B. N. Methods in Enzymology: Complex 
Carbohydrates; Neufeld, E.; Ginsburg, V., Eds.; Academic 
Press: New York, 1966, Vol. VIII 115.
(43) Nicotinamide 5-Phenylbenzimidazole Dinucleotide (26): 
The product was isolated after 48 h in 43% of yield. 1H NMR 
(400 MHz, D2O): δ = 8.86 (s, 1 H), 8.67 (s, 1 H), 8.58 (s, 2 
H), 8.09 (s, 1 H), 7.85 (s, 1 H), 7.29–7.68 (m, 9 H), 5.91 (s, 
1 H), 5.52 (s, 1 H), 3.94–4.42 (m, 10 H). 31P NMR (162 
MHz, D2O): δ = –11.09 to –11.60 (m, P–O–P). HPLC: tR = 
8.87 min. MS (ES): m/z [M]+ calcd for C29H33N4O14P2+: 
723.1469; found: 723.1436.
(44) Aplysia cyclase was purchased from Sigma-Aldrich. The 
incubation reactions were monitored by HPLC (SAX 
column, 5% MeOH; 50 mM KH2PO4, pH 4). The enzymatic 
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assays were conducted in TEAB buffer (0.1 M, pH 7.2) and 
used 1 mL solution containing 100 mM of NAD+ analogues, 
and 10 μL of reconstituted enzyme in buffer (ca. 300 
units/mL).
(45) Pesnot, T.; Kempter, J.; Schemies, J.; Pergolizzi, G.; Rumpf, 
T.; Uciechowska, U.; Sippl, W.; Jung, M.; Wagner, G. K. 
J. Med Chem. 2011, 54, 3492.
(46) Dölle, C.; Rack, J. G. M.; Ziegler, M. FEBS J. 2013, 280, 
3530.
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